| 13.6 -2.19 (-13.87%) | 04-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.04 |
1-year : | 20.14 |
| Resists | First : | 14.59 |
Second : | 17.25 |
| Pivot price | 13.04  |
|||
| Supports | First : | 10.3 |
Second : | 8.56 |
| MAs | MA(5) : | 13.5 |
MA(20) : | 12.84 |
| MA(100) : | 10.56 |
MA(250) : | 7.43 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 53.1 |
D(3) : | 56.6 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 17.25 | Low : | 3.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DSGN ] has closed below upper band by 33.2%. Bollinger Bands are 92.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.8 - 15.87 | 15.87 - 15.94 |
| Low: | 13.4 - 13.49 | 13.49 - 13.57 |
| Close: | 13.47 - 13.61 | 13.61 - 13.72 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Thu, 30 Apr 2026
Design Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:DSGN) 2026-04-30 - Seeking Alpha
Wed, 29 Apr 2026
Earnings call transcript: Design Therapeutics beats Q1 2026 EPS expectations - Investing.com
Tue, 28 Apr 2026
Design Therapeutics 1Q Loss/Shr 29c >DSGN - Moomoo
Tue, 28 Apr 2026
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates - The Manila Times
Tue, 28 Apr 2026
Design Therapeutics (NASDAQ: DSGN) Q1 loss, $223M cash and GeneTAC pipeline updates - Stock Titan
Tue, 28 Apr 2026
Cash runway into 2029 as Design Therapeutics (NASDAQ: DSGN) advances trials - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 33.3 (%) |
| Held by Institutions | 62.3 (%) |
| Shares Short | 2,080 (K) |
| Shares Short P.Month | 1,740 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.51 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.96 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -11.15 |
| PEG Ratio | 0 |
| Price to Book value | 3.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|